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Abstract
Health research in sub-Saharan Africa takes place against aBackground: 
lengthy history of exploitation and unfair collaboration. This has involved the
export of samples and data from the continent for the benefit of institutions
and researchers elsewhere. In this paper, we report the perspectives of
people involved in conducting genomics research in Zambia and the
capacity of the Health Research Act (HRA) of 2013 in regulating genomics
research.
: We approached 14 purposively selected stakeholders involvedMethods
in the development or implementation of the HRA in Zambia for in-depth
interviews. These were members of research ethics committees, genomics
researchers, Ministry of Health policy makers and institutional lawyers.
: Participants reported that there are benefits in genomics researchResults
for Zambia such as diagnosing and treatment of diseases. Participants also
expressed concerns, most of which were ethical in nature. Prominent
concerns were on consent. Participants’ main concern was the possible
misuse of samples in the future. These concerns resonated with the HRA,
which prohibits the use of broad consent for the collection of samples and
data for future unspecified research. The implications of this is that
Zambians may not participate in any kind of health research for which the
storage, sharing and re-use of data or samples is envisaged. The restrictive
nature of HRA means that genomics research may be excluded from future
health research collaborations, thus isolating the country from potentially
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health research collaborations, thus isolating the country from potentially
beneficial health research. Some policy makers also worried the samples
and data that comes from such research may be difficult to access by local
scientists.
: In this article, we describe the views of Zambian policymakersConclusion
on genomics research and the capacity of HRA in regulating genomics
research. Our findings are relevant for the Zambian audience, and other
African countries that are aiming to regulate health research, especially
genomics research.
Keywords
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Introduction
Health research in sub-Saharan Africa takes place against a 
lengthy history of exploitation and unfair collaboration. Charac-
terizing this trend is a history of export of samples and data from 
the continent for the benefit of institutions and researchers else-
where (Heymann et al., 2016; Munung et al., 2017). While the 
H3Africa initiative aims to establish biobanks in Africa, much 
other genomics research, where the export of samples and data 
for use elsewhere, continues to be common, partly because of 
mandatory policies for the sharing of samples and data. Con-
sidering such trends, genomics research is seen as perpetuating 
biocolonialism (Van Rinsum & Godfrey, 2004)
As the birthplace of modern humans and the home of the great-
est human genomic diversity, the African continent is a logi-
cal focus for efforts aimed at improving diversity, inclusion, 
and representation in genomics research (Bentley et al., 2019). 
Meanwhile, African policymakers involved in the regulation of 
health research struggle to make sense of the need to, on the one 
hand, promote health research and collaboration, but on the other 
hand protect researchers and the general public from (perceived 
and/or real) exploitation. A particular challenge in this regard 
is that the human capacity and infrastructure required to suc-
cessfully conduct genomics research remains concentrated in 
particular African countries (Aron et al., 2017), with others relying 
on collaboration to make this happen (Yakubu et al., 2018).
Several authors have described how different regulatory regimes 
across the continent strike a balance between these appar-
ently opposing tensions (Barchi & Little, 2016; Nienaber, 
2011; Staunton & Moodley, 2013). Whilst many African coun-
tries have not effectively regulated the export of samples 
and data, others have created regulatory frameworks that are 
progressive – for instance, Rwanda, Ethiopia, Uganda, and Nigeria 
have introduced regulation that strikes a balance between pro-
moting research whilst protecting national interests (de Vries 
et al., 2017). The picture that emerges from such analyses is 
that, overall, African countries tend to be permissive towards 
genomics research and its associated policies regarding the stor-
age, redistribution, and re-use of samples and data for future 
unspecified research. They are also actively or passively permis-
sive towards the use of broader forms of consent to allow the 
re-use of samples and data (Tindana & de Vries, 2016).
A notable exception is Zambia, which has specifically regu-
lated against key policy components of health research. In 2013, 
the Health Research Act No 2 of 2013 of the Laws of Zambia 
(henceforth the HRA 2013) came into effect. As is evident 
from the name, this law specifically regulates health research 
and is one of the few specific health research acts on the 
continent. Although the HRA 2013 is a comprehensive law 
that aims to afford protections for the Zambian population, 
there are two components of this Act that challenge the con-
duct of genomics research in Zambia (Chanda-Kapata et al., 
2015). The first is a requirement that no biological materials 
may be collected for ‘future unspecified health research’ 
(HRA Section 47(1)) – effectively prohibiting the use of blan-
ket, broad or tiered consent (although exactly what counts as 
‘unspecified’ could be debated). The second relates to tight regu-
lations around the storage, export, and re-use of tissue samples. 
For instance, biological materials may not be stored for ‘unspeci-
fied storage’ (HRA Section 47(1)) and may only be exported 
under strict conditions.
The overall gist of the legislation seems to be to promote 
Zambian domestic research capacity, including Zambian’s abil-
ity to store, process and use samples and data. Yet in a com-
mentary on the HRA, Chanda-Kapata et al. (2015) articulated a 
concern that these provisions could have a dampening effect on 
genomics research in Zambia. Anecdotally, we know of 
instances where the strict regulatory environment has already 
impacted on genomics research conducted in the country, 
with Zambians being excluded from participating in interna-
tional health genomics research that could have generated find-
ings relevant to Zambians’ health. Against this background, we 
explored the perspectives of policy makers and regulators on the 
benefits of genomics research, as well as the concerns and 
the capacity of the HRA in conducting genomics research 
in Zambia. Such research is important in order to provide an 
opportunity for research stakeholders, e.g. policy makers, 
researchers, ethics committee members, to share their reflec-
tions on advances in genomics research and the implications for 
(and of) the existing laws and regulations.
Methods
To investigate our study aim, we employed a qualitative case 
study approach where we approached a range of stakeholders 
involved in genomics research and in the development or imple-
mentation of the HRA in Zambia for in-depth interviews. Spe-
cifically, we invited members of research ethics committees, 
researchers in genomics, Ministry of Health policy makers and 
an institutional lawyer to participate in this study.
Study site
The study was conducted by the Department of Health Pro-
motion and Education at the University of Zambia and the 
University of Cape Town. We interviewed participants from 
selected institutions in Zambia in their various locations.
Study sample
The study reported here was part of a larger study in which 
we also interviewed participants in a rheumatic heart dis-
ease genomics study, reported in Mweemba et al. (2019). 
Here, we report on findings resulting from in-depth interviews 
with people involved in the regulation or implementation of 
research policies for genomics research and generally health 
research in Zambia.
We approached 16 participants to participate in the study, but 
only interviewed 14 participants. The other two, despite accept-
ing to participate, were constantly busy and mostly out of the 
country. Among the 14 we interviewed, some had dual roles: 
7 members of institutional Research Ethics Committees (5 
of them were also health researchers with experience in con-
ducting and reviewing genomics research); 5 members of the 
Zambian National Health Research Ethics Committee (NHREC) 
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(3 of whom also served on an institutional committee); 2 scien-
tists involved in genomics research; 1 member of the Ministry of 
Health involved in the development of the HRA; 1 community 
representative; and 1 institutional lawyer. We initially identi-
fied participants using our own network and knowledge of the 
Zambian environment and then asked key interviewees for sug-
gestions as to who else to speak with (snowball sampling). While 
each interview contributed unique perspectives on the topics 
discussed, we started reaching saturation on most topics by the 
10th interview. Nevertheless, we continued with four more not 
only to increase diversity of participants but also to ensure that 
we reached saturation on all the key issues in the study.
Interested participants were contacted by phone to explain the 
study and schedule an appointment. Specifically, in the inter-
views, we explored participants’ views on genomics research 
and broad consent in the context of health research and the his-
tory and capacity of the Zambian Health Research Act of 
2013 to regulate genomics in Zambia. Interviews were con-
ducted between June and December 2017. The specific topics 
discussed included perspectives on genomics and bio-banking 
research, data and sample sharing, consent models for genomics 
research, the health research Act of 2013, and international col-
laborations and governance issues (see Extended data: interview 
guides (Mweemba et al., 2020)). The first author (OM) inter-
viewed all the participants. He has a PhD in Social Science and 
Health and has extensive experience in qualitative interview-
ing on complex health research topics. At the time of the study, 
he was a Lecturer in the Department of Health Promotion and 
Education at the School of Public Health, University of Zambia. 
OM had well-established relationship with all the participants 
as fellow researchers and colleagues dating many years to 2012. 
The typical duration of the interviews was about 30 minutes. 
All interviews were conducted privately in the respective 
offices of the different participants.
Data analysis
All interviews were audio-recorded and notes written dur-
ing the interviews. All interviews were transcribed verbatim. 
Transcripts were not returned to participants for checking. Fol-
lowing transcription, text files were imported into NVivo 11 
(QSR International Pty Ltd, 2015) as part of the larger dataset 
including interviews not analysed for this paper (see Mweemba 
et al., 2019). Two researchers (OM and JdV) independently 
coded five transcripts, including two transcripts from the par-
ticular dataset analysed for this paper. Following discussions, 
we developed a hierarchical coding scheme together with a 
codebook (see Extended data (Mweemba et al., 2020)) describ-
ing each code and its relationship to overarching study themes. 
Interviews were then coded by the researchers and two 
research assistants. Two researchers (OM and JdV) together 
analysed and interpreted coded data using the Framework 
Method functionality embedded in NVivo 11 (Gale et al., 2013; 
Smith & Firth, 2011). We discussed data interpretations with 
the wider study team.
Ethics approval and consent
All the participants provided written consent after explaining 
the purpose of the study, including the possible risks and 
benefits of the study. A signed copy of each set of consent 
documents were kept by the study participants. We obtained 
ethics approval for this study from the University of Cape Town’s 
Faculty of Health Sciences Health Research Ethics Committee 
(approval number FHS644-2015) and the University of Zambia 
Biomedical Research Ethics Committee (approval number 
001-09-2016).
Results
The results below are presented in three inter-related broader 
themes: the benefits of genomics research in Zambia; con-
cerns about genomics research; and the Zambia National Health 
Research Act and regulation of genomics research in Zambia.
The benefits of genomics research in Zambia
The participants largely understood genomics research in the 
context of health research as a scientific approach to determin-
ing the genetic causes of diseases. Some participants also indi-
cated that genomics research could help develop and target 
health policies and devise health promotion support programs 
for individuals and groups with the potential to be affected 
by a particular disease or health condition. Overall, partici-
pants seemed to agree that there is value to promoting genomics 
research in Zambia because of its likely benefit for the Zambian 
population.
     It’s a very important area in that you’re trying to find out 
the genetic determinants of disease you know […] in Africa 
I think it’s an area that hasn’t been very well explored … 
but it could generate quite useful information that can 
help us in disease prevention, disease treatment, manage-
ment of patients with particular conditions… I believe that 
we cannot do without genomics research, it is extremely 
important (Researcher and former Research Ethics 
Committee member).
Participants also suggested that Zambian researchers should 
be supported to participate in international genomics research 
collaborations.
      If we are to understand disease dynamics, sometimes 
we need to do those studies. If we are to develop treat-
ments for certain diseases, we need to know how these 
drugs operate in the human body, what changes happen 
in the chromosomes and so on… For clinical practice, 
if I could relate to drugs that is what I understand better 
yes probably because that could help us now individual-
ise the management of patients. So as a medical person I 
think we need to encourage genomics research. (Researcher 
and Research Ethics Committee member).
Concerns about genomics research
Whilst recognizing its potential benefits, the participants also 
expressed concerns about genomics research and most of these 
were of an ethical nature. The issue of consent was raised fre-
quently. Although less controversial than blanket consent, par-
ticipants were concerned about consent for future unspecified 
studies (be that through broad or tiered consent) with the 
main concern being the possible misuse of samples in the 
future.
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     Those are some of the issues that come up when you are 
talking about genomics research and it creates a prob-
lem […] you can’t get consent for every single thing you 
are going to do in future from the patient but if there is a 
mechanism to perhaps get consent from the ethics commit-
tee for each new type of study that might be helpful because 
then you have a situation where a researcher wants to 
go overboard and to do things wrong. But that is still 
not enough because some people might still do wrong 
things anyway (Research Ethics Committee member).
Interestingly, participants framed informed consent as being 
one way of protecting against sample misuse:
     There is a likelihood that things that the person has not 
consented to are going to be done and of course we have 
had this issue that has been discussed left right and cen-
tre of how people from the western world, for example, 
want to manipulate Africans by coming here and har-
vest samples and things like that. Many people are in 
a way duped so to say because they may be enticed with 
something and they give these samples (Institutional 
Lawyer).
Issues around consent were also framed in terms of an ‘attach-
ment’ of participants to their samples. The risk is that partici-
pants could lose trust in the research system if samples were used 
indiscriminately.
     I think the issues of people have this attachment to their 
samples, their blood and most of their concerns lie 
from say maybe no trust or lack of trust based on maybe 
unknown things or stigma and so some of the ethical 
issues that come up will be if there is no disclosure what 
would the patient think if they found out later on that their 
blood has been used for a specific type of research which 
they did not approve or they find offensive…maybe 
offensive to their culture or their religious beliefs 
(Research Ethics Committee member).
Because of some of the concerns raised, specific consent was 
insisted upon as a possible solution to these concerns. Specific 
consent is defined as consent for a particular research ques-
tion as opposed to for instance tiered or broad consent, which 
allow for the re-use of samples and data for other research 
questions also.
     We have to specify what exactly the individual is consent-
ing to, what can be done on that particular specimen they 
are submitting or they are donating and specifically that 
they would like the specimen to be used for the particular 
condition the participant consented for (Former Research 
Ethics Committee and NHREC member).
     Let us be specific and let us predict a bit what we are think-
ing so that you don’t just hear people saying no we will 
put it in the bio-bank until 2021, what you are going to do 
in 2021. Just state and discuss things so that people know 
where you are going and what you are going to do 
(Research Ethics Committee and NHREC member).
Participants also framed concerns over sample sharing and 
export in terms of sample misuse and specifically the poten-
tial for samples and data to be used in ways that reflect badly on 
Zambia, or on particular communities.
     [In one genomics study we reviewed], I think that was 
the one where the samples were going to be shipped 
off to somewhere […] Some people feel that by doing 
that you are surrendering ownership to somebody else 
and of course they felt that maybe some of the research 
will not be in good light in terms of people trying to 
find a way of dealing [harm] with you, by looking at the 
genetic make-up (Researcher and former Research Ethics 
Committee member).
In this quote, ‘dealing with you’ is a commonly used reference 
to the historical colonization of Zambia.
Many of the participants placed emphasis on the importance of 
control and ownership by Zambian researchers and regulatory 
institutions over samples and data, which could leave samples 
open to abuse by unscrupulous researchers.
     Earlier there was a suspicion that was associated with 
genomics research that, “Why are people getting these 
samples, sending them abroad for analysis and so on, what 
else are they going to do there because once the samples 
leave the country; we have no control on what happens… 
[…] we are not able to regulate [whether] they adhere 
to what they have said they are going to do out there” 
(Research Ethics Committee member).
Such concerns were articulated not just in relation to the export 
of samples but also to the sharing of genomic data. Impor-
tant in the context of the latter were concerns about benefits, 
sometimes articulated as intellectual property rights.
      This information leaves the country and we have no say. 
That’s a security issue but also just intellectual prop-
erty, what happens to the information that you generated 
from this? Do we get any benefits from it, can we use it 
to better the lives of our people? (Senior Government 
Official and Policy Maker).
Building on a broader question of benefits and benefit shar-
ing, participants questioned whether samples and data would 
likely still be available to Zambian researchers or students for 
further research. Past experience is that it is difficult for local 
researchers to access samples and data from Zambia that is 
stored and distributed from other countries, tapping into 
broader concerns about exploitation and fairness in collaboration.
      We have had situations where data that is produced, here 
in Zambia, people are having problems accessing it. But 
when you go to the North you find the same data […] 
easily accessible […]. Another experience is… you have 
this data set which you enter online but once it gets into 
the database you can’t access the whole database. The 
database server is in [somewhere in the North]… they 
have the monopoly on the data and the only thing you can 
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do is create the data which you can’t access (Researcher, 
Research Ethics Committee member and former 
NHREC member)
The National Health Research Act and regulation of 
genomics research
Amidst these concerns, the participants commented on the 
appropriateness and adequacy of the National Health Research 
Act of 2013 in regulating genomics research in Zambia. 
Importantly, out of the 14 interviewees – all of whom were 
involved either with the development of the Act or are charged 
with its implementation as members of ethics committees 
– about eight participants were conversant with the law and 
the rest had general ideas about it. All the eight participants 
who were conversant with the law were involved either with the 
development of the Act or its implementation.
The Act was drafted following an increasing number of clini-
cal trials and other health research projects being conducted 
in Zambia, and the realisation by key stakeholders (some of 
whom we interviewed) that the existing regulations were not 
adequate to regulate such research. A specific concern at the 
time related to the export of samples for further analysis to other 
countries that had stronger laboratory capacity.
      There was this rampant exportation of samples with-
out regulation it was therefore important that there 
had to be regulation in terms of biological materials. 
Secondly […] as the National Health Ethics Commit-
tee was developed, it recognised that there was no legal 
framework in which the ethics would be empowered to 
follow-up studies, hence the need formulate the Act. So, 
it was discovered that actually in Zambia at that par-
ticular time there was generally no law which allowed 
for research on human beings. So, there was a time 
that research in live human beings was suspended until 
we came up with this (Researcher and former NHREC 
member).
Participants described that the Act had been important in reg-
ulating the export of samples with specific agreements on 
how the samples will be used detailed in the now-mandatory 
Material Transfer Agreement.
     There was a suspicion that was associated with genomics 
research that why are people getting these samples, send-
ing them abroad for analysis, what else are they going 
to do […] So I think that was the major concern by the 
committee at the time but it has since reduced because 
I think the modalities of exporting samples now are becom-
ing a bit stringent yes with the coming of the material trans-
fer agreement. […] I think samples were just going out 
without any regulations but now they are being regulated 
(Research Ethics Committee member).
Yet participants also described that once enacted, the new Act 
brought about considerable debate and controversy in Zam-
bia, particularly about: the ownership of data and samples by 
the government; approval of publications by the government; 
and tightening regulations about the establishment of biobanks.
     I think there's a statement which says that "specimens 
belong to the Government of the Republic of Zambia" 
which in essence actually says government should have 
jurisdiction on what happens to specimens once they have 
been collected and then secondly there is I think there 
is a part which says that before any publication, before 
you can publish data arising from a particular research, 
there should be authorisation by the Ministry of Health 
[…]. That was seen as if it is stifling research and pub-
lications (Researcher and former Research Ethics 
Committee member).
Another point of debate related to the prohibition to collect 
specimens for ‘unspecified health research’. Our research par-
ticipants described that some provisions of the Act were at odds 
with genomics research policies, including the use of consent 
for future use of samples and data which is not allowed in the 
Act. Part of the reason for these restrictive policies was that at 
the time of its development, knowledge on genomics research 
was not common, which explains why some restrictions 
were at odds with the requirements of such research.
     Probably at the beginning when these guidelines and 
these provisions were being drafted, there was no clear 
understanding of what genomic research was all about 
because for example if you say you are not going to 
allow submission or transportation of samples to a 
particular biobank even if it’s for genetic research then 
in essence what you are saying is each particular coun-
try should hold their samples, you know but I mean there 
are some conditions which are cross-cutting and […] 
common in a particular region and I don’t think its cost-
effective to have biobanks in each country (Researcher 
and former NHREC member).
Participants also highlighted that because the Act had no juris-
diction beyond the borders, this made it difficult to monitor 
and regulate the use of samples once they leave the coun-
try, including ensuring that the researchers adhere to terms of 
the agreement on the use of samples. Importantly, the partici-
pants acknowledged that the stringency of the Act may preclude 
Zambians from effectively engaging in genomics research.
     I think that discussions [to consider changes] on that 
started after the Livingstone meeting1 […] that's when well 
a lot of people realized that our colleagues in the region 
have been engaged in genomic research for some time 
and we believe that there is a lot of good that can come 
out of that particular research and at the same time 
we understand that and believe that we are part of the 
1
 The H3Africa Consortium organized a series of engagement meetings with 
members of ethics committees and policymakers from across the continent. For 
a description of the Livingstone meeting, see De Vries J, Littler K, Matimba 
A, McCurdy S, Ouwe Missi Oukem-Boyer O, Seeley J, Tindana P: Evolving 
perspectives on broad consent for genomics research and biobanking in Africa. 
Report of the Second H3Africa Ethics Consultation Meeting, 11th May 2015. 
Global Health, Epidemiology and Genomics 2016, 1(e13):1-3.
Page 6 of 9
AAS Open Research 2020, 3:32 Last updated: 24 JUL 2020
global village; conditions that affect our people here that 
we feel that the solutions, could be partly found from 
genomic research but then given, the stringency of our 
regulations it was going to be very difficult for us as a 
country to participate in genomic research (Researcher and 
former Research Ethics Committee member).
Yet against such concerns, participants felt it was really impor-
tant to ensure that Zambian researchers are protected and that 
there are provisions in place that would ensure the long-term 
reversal of a trend of sample extraction without benefits to 
Zambian researchers or the general public.
     You cannot perpetually be transferring materials we 
need to make sure that the Zambian institutions are also 
empowered. It means that if we know that in future stud-
ies we are going to need this, it is better to make arrange-
ments that that equipment is brought in the country 
and then for future studies we don’t have to ship materials 
outside (Institutional and NHREC member).
One way in which the Act protects Zambian investigators is by 
requiring that international research collaborations involve a 
Zambian investigator based in a local institution.
     As much as the Act is limited it at least touches on all 
these things, one of the things that it talks about the col-
laboration that whenever there is a study going on in the 
country there should at least be a Zambian either the 
PI or the Co-PI should be a local individual who is 
placed here who can be traced to actually have research 
contacts in the country.... (Senior Government Official 
and Policy Maker).
Generally, the policymakers we interviewed acknowledged that 
the Act in its ‘current’ form was limited in its ability to provide 
adequate regulation of genomics research. At the same time, 
however, some policymakers acknowledged that it would take a 
long time to amend the law. In view of this, some policymakers 
were optimistic that genomics research can be approved despite 
the legal circumstances if a convincing case is made by research-
ers to the ethics committee, as was the case with the Rheumatic 
Heart Disease Genomics study conducted at the University 
of Zambia (see for instance Mweemba et al., 2019).
     There have been some discussions which say that they are 
[moving] towards amending the law but you know how 
long it takes to even just enact a law later on, it requires 
political will so our hope is that once the authority, 
because the law provides for the national health research 
authority to be put in place, once that is put in place and 
starts running the people within that authority will be 
able to move the agenda… in a case where researchers 
put their case convincingly to the ethics committee, the 
reasons are ok, the study is justified. I don't see the ethics 
committee refusing to do this kind of study… I believe that 
the ethics committee can do that if they know what they 
are doing by making sure that information is anonymous 
cannot be traced back to the individuals and if it comes 
out, it comes out in such a way that doesn't stigmatise 
the whole community (Former NHREC member).
Interestingly, participants described how they sought to navi-
gate this prohibition by seeking to get some clarity – at a broad 
level – of what future research could be conducted.
     [The law] says that samples shall not be collected for 
unspecified future studies and so we have problems to 
reconcile that with the need to facilitate research but 
what we would advise people would be to try to be 
as specific as they could. You know you cannot predict 
what you are going to do in future but if you can go some 
way towards specifying then, we would approve. But if 
it’s completely blank like unspecified future studies then 
we would be going against the spirit of the law and we 
would not approve. That is not to say that the law is ok as 
it is, it might need to be reviewed but because it is currently 
the law you have to still meet the requirements (Former 
NHREC member and serving member of an Institutional 
Ethics Committee).
The participants recommended that what was needed is to 
strengthen the regulatory system overall and specifically for 
genomics research. They suggested that new guidelines should 
be developed specifically aiming to address the issues that arise 
in genomics research including broad consent, sample and data 
sharing, sample storage and the feedback of results.
     Well, probably the best approach would be to have national 
guidelines on genomic research […] so that when we are 
for instance reviewing genomics research we know that 
these are the guidelines that should apply (Research 
Ethics Committee member).
Importantly, it was also argued that guidelines governing 
research collaborations ought to be developed which detail issues 
such as data and sample ownership, agreements about publi-
cations and authorship and so forth. These regulatory frame-
works should include mechanisms for regulating the samples 
that leave the country including biobanks that are situated in 
other countries and that contain samples from Zambia.
Discussion
The empirical data generated by our study reflects partici-
pants’ perspectives on genomics research as well as the con-
cerns and the effect and capacity of the NHA to regulate 
genomics research. Although participants agreed that there is 
value in promoting genomics research in Zambia, they also 
expressed concern over key ethical issues that such research 
raises. Primary amongst these was a worry about the poten-
tial for genomic resources to be misused in ways that offend the 
culture or religion of research participants, or that may be stig-
matising or exploitative in nature. Importantly, such concerns 
suggested the need to manage tension between the need for con-
trol and protection on the one hand and permissive policies 
that allowed to facilitate collaboration. In an under-resourced 
country like Zambia where there are no large-scale sequenc-
ing facilities available, the export of samples for genotyping or 
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sequencing may be the only way to ensure the inclusion of 
Zambian research participants in genomics research. An alterna-
tive would be large-scale and long-term government investment 
in genomic research infrastructure.
Perhaps the reason our participants were concerned about sam-
ple export can be explained by the emphasis they placed on the 
importance of oversight and ownership by Zambian research-
ers and institutions over samples and data. They described 
that a problematic feature of sample export is that Zambian 
regulatory institutions lose ‘control’ and that this could leave 
samples open to abuse by unscrupulous researchers. Impor-
tantly, however, participants struggled to give examples of what 
would constitute abuse. Our findings align with those by Tindana 
et al. (2014) who also revealed that given the inevitable uncer-
tainty of future uses, perceptions of unfairness in who gains 
from sample export and storage, and fears of losing control 
of samples after export were expressed by their participants 
in a study conducted in Ghana and Kenya.
Due to the nature of genomics research, it involves the establish-
ment of large and diverse scientific networks bringing together 
diverse and interdependent forms of expertise and institu-
tions in higher and lower-income countries. Participants were 
concerned about the lack of capacity of local researchers to 
meaningfully participate in international collaborative genom-
ics research. Out of concern over historic exploitation and 
perpetuation of inequalities by sending African samples to 
non-African laboratories (Matenga et al., 2019; Okeke, 2016), 
some African nations have strict guidelines regulating the export 
of samples (de Vries et al., 2017). Petti et al. (2006) suggest that 
performing laboratory tests locally or at least regionally 
gives greater African ownership of studies and high income 
countries collaborators need to help build research capacity.
Regarding the Health Research Act No 2 of 2013 of the Laws of 
Zambia, although a comprehensive law, the prohibitive provi-
sions on the use of broad consent for the collection of samples 
and data for future unspecified research and the tight regula-
tions around the storage, export, and re-use of tissue samples 
means that Zambians are currently restricted in their involve-
ment in any kind of health research for which storage, sharing 
and re-use of data or samples is envisaged. Yet sharing, stor-
age and re-use of samples and data are an increasingly common 
component of health research globally, including in clinical tri-
als research, genomics, and research on emerging drug resistance 
for instance. A worry is that the strict regulatory environ-
ment in Zambia could mean that the country and its research-
ers are avoided in future health research collaborations, thus 
isolating the country from potentially beneficial health research.
Interestingly, our participants did not seem to share this con-
cern and generally supported this provision of the Act. The con-
sent and export restrictions of the Act were conceptualised as 
important ways of protecting Zambian research participants and 
researchers from exploitation by researchers and institutions in 
other countries – and mainly in high-income countries. They 
were also seen as appropriate means to protect individuals 
against research that could lead to stigma or that could otherwise 
be seen as offensive from a cultural or religious perspective. 
This narrative is not unique to Zambia. It also been reported 
in other studies from other countries (Moodley et al., 2014; Igbe 
& Adebamowo, 2012). This suggest that the legacy of exploit-
ive research in Africa still lingers in the minds of regulators 
and policy makers.
Our study suggests that the legislation is arguably not the best 
way to guard against perceived and actual unfair research prac-
tices, especially in the field of health research that is con-
stantly changing. Regulation that has the ability to adapt 
to these changes may be better suited for that purpose. But 
beyond that question, what stands out is that health research 
in Zambia takes place against a context of deep mistrust in 
the intentions and integrity of international researchers. The 
open science policies on which genomics is premised – involv-
ing sharing, storage and future use of samples and data – need 
to take account of this reality.
Conclusion
The results of this research suggest that although most of the 
stakeholders we interviewed agreed that conducting genom-
ics research in Zambia could be beneficial, some concerns were 
expressed around the nature of consent for these types of studies 
and the potential for misuse of samples in future. Though these 
concerns resonated with the HRA, which prohibits the use 
of consent for the collection of samples and data for future 
unspecified research, some participants indicated that the 
HRA in its ‘current’ form was limited in its capacity to regulate 
genomics and bio-banking research in Zambia.
Our findings are relevant not just for the Zambian audience, but 
also for those in other African countries that are aiming to regu-
late health research especially genomics research. Specifically, 
we hope that this paper has provided some aspects that need 
to be considered in national regulation of genomics research 
including control over samples and data. We also hope future 
international collaboration in genomics research will consider 
the concerns that arise from this study.
Data availability
Due to the small number of interview participants who also 
hold strategic positions in Universities, Governments and in 
the community, sharing their information will compromise 
their identity and raise confidentiality and privacy concerns for 
the participants, and hence jeopardise their position or their 
role in their organisations. We have provided information in form 
of quotes, but these are highly anonymised to protect the par-
ticipants’ identities. The University of Zambia Biomedical Eth-
ics Committee that approved this study, approved it under the 
strict terms of maintaining privacy and confidentiality and their 
default position for ethical approval does not include data shar-
ing unless its specifically requested for and justifications for 
doing should be provided. Unfortunately, for these interviews, 
data sharing was not requested for because of the nature of inter-
views, which identifies the participant’s role in their organi-
sation and their identities, as stated above. Those interested 
may contact us for any clarifications on the research data, 
and we can share only broader and processed information to 
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protect the identity of individual participants and their institutions, 
such as matrix tables, summaries of themes and further quotes 
on specific topics. We will also be happy to share the data col-
lection tools used in the study and the code book we generated 
for this paper (see Extended data (Mweemba et al., 2020)).
Extended data
Figshare: Extended data for the Genomics Study in Zambia, 
http://www.doi.org/10.6084/m9.figshare.12639200.v1 (Mweemba 
et al., 2020).
-     Interview Guide Research Regulators V2
-     Interview Guide Research Ethics Committee Members/
Researchers V2
-     Codebook
Reporting guidelines
Figshare: COREQ checklist for ‘Policy makers, regula-
tors and researchers’ perspectives on genomics research and 
the capacity of the National Health Research Act of 2013 to 
regulate genomics research in Zambia’, http://www.doi.org/10.6084/
m9.figshare.12639200.v1 (Mweemba et al., 2020).
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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